FATE THERAPEUTICS INC

FATE ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-43.0M $-33.5M $-30.0M $-25.9M $-20.9M $-14.2M $-13.4M
Depreciation & Amortization $971.0K $881.0K $687.0K $496.0K $571.0K $590.0K $672.0K
Depreciation
Amortization
Stock-Based Compensation $2.4M $2.4M $1.6M $155.0K $172.0K
Net Cash from Operating Activities $-36.8M $-29.8M $-18.4M $-22.4M $-15.4M $-13.3M $-12.1M
Investing Activities
Capital Expenditures $1.7M $457.0K $1.5M $882.0K $244.0K $709.0K $2.0K
Business Acquisitions
Net Cash from Investing Activities $-10.2M $-4.1M
Financing Activities
Dividends Paid
Stock Repurchases $7.0K
Net Cash from Financing Activities $47.4M $57.7M
Net Change in Cash $343.0K $23.8M $15.7M $-4.9M $44.9M $2.7M $-4.8M
Free Cash Flow $-38.5M $-30.3M $-19.9M $-23.3M $-15.6M $-14.0M $-12.1M
← Newer Page 2 of 2 Older →